Mechanisms, manifestations, and management of digoxin toxicity in the modern era

被引:65
作者
Bauman J.L. [1 ,2 ,4 ]
DiDomenico R.J. [1 ,2 ]
Galanter W.L. [3 ]
机构
[1] Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL
[2] Department of Medicine, Section of Cardiology, University of Illinois at Chicago, Chicago, IL
[3] Department of Medicine, Section of General Internal Medicine, University of Illinois at Chicago, Chicago, IL
[4] University of Illinois at Chicago, m/c 886, Chicago, IL 60612
关键词
Digoxin; Clinical Decision Support System; Digoxin Concentration; Computerize Physician Order Entry; Serum Digoxin Concentration;
D O I
10.2165/00129784-200606020-00002
中图分类号
学科分类号
摘要
Because of the common use of digoxin and because of its narrow therapeutic index, digoxin toxicity has been prevalent historically and, therefore, most clinicians are well aware of the classical dose/concentration-related signs and symptoms of toxicity. Yet, in the modern era the incidence of digoxin toxicity has been declining for a variety of reasons, including a new (lower) therapeutic range, the development of more effective drug therapies for heart failure, and more accurate dosing methods. In addition, digoxin toxicity, once commonly fatal, can now be quickly and effectively treated by the emergency administration of antidigoxin Fab fragments. Indeed, it may be possible to expand the use of Fab fragments to select patients with non-life-threatening digoxin toxicity, in order to save costs and improve patient comfort. Most cases of digoxin toxicity are caused by inappropriately high dosages, which are usually prescribed in the setting of renal dysfunction, while other cases can be attributed to system errors such as multiple prescriptions, poor patient counseling, or errors in transcribing. With modern computerized prescribing systems, such as direct physician order entry and prompts that alert the clinician to the potential for error, it is possible to decrease the incidence of digoxin toxicity even further. A realistic goal is to nearly eradicate once commonplace digoxin toxicity or at least make its occurrence a rare event. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:77 / 86
页数:9
相关论文
共 61 条
[1]  
Smith T.W., Haber E., Digoxin intoxication: The relationship of clinical presentation to serum digoxin concentration, J Clin Invest, 49, pp. 2377-2386, (1970)
[2]  
Beller G.A., Smith T.W., Abelmann W.H., Et al., Digitalis intoxication: A prospective clinical study with serum level correlations, N Engl J Med, 284, pp. 989-997, (1971)
[3]  
Duhme D.W., Greenblatt D.J., Koch-Weser J., Reduction of digoxin toxicity associated with measurement of serum levels: A report from the Boston Collaborative Drug Surveillance Program, Ann Intern Med, 80, pp. 516-519, (1974)
[4]  
Jelliffe R., A mathematical analysis of digitalis kinetics in patients with normal and reduced renal function, Math Biosci, 1, pp. 305-325, (1967)
[5]  
Jelliffe R.W., An improved method of digoxin therapy, Ann Intern Med, 69, pp. 703-717, (1968)
[6]  
The effect of digoxin on mortality and morbidity in patients with heart failure, N Engl J Med, 336, pp. 525-533, (1997)
[7]  
Adams Jr. K.F., Gheorghiade M., Uretsky B.F., Et al., Clinical benefits of low serum digoxin concentrations in heart failure, J Am Coll Cardiol, 39, pp. 946-953, (2002)
[8]  
Rathore S.S., Curtis J.P., Wang Y., Et al., Association of serum digoxin concentration and outcomes in patients with heart failure, JAMA, 289, pp. 871-878, (2003)
[9]  
Smith T.W., Antman E.M., Friedman P.L., Et al., Digitalis glycosides: Mechanisms and manifestations of toxicity. Part I, Prog Cardiovasc Dis, 26, pp. 413-458, (1984)
[10]  
Smith T.W., Antman E.M., Friedman P.L., Et al., Digitalis glycosides: Mechanisms and manifestations of toxicity. Part II, Prog Cardiovasc Dis, 26, pp. 495-540, (1984)